Table 1.
Baseline demographics and disease characteristics of the overall population
| Placebo‐controlled studies (randomized controlled trials) | OLE studies | |||
|---|---|---|---|---|
| Placebo or placebo + TCS | Dupilumab or dupilumab + TCS | Combined | Dupilumab | |
| Total number | 1166 | 2307 | 3473 | 3045 |
| Age (years), mean (SD) | 33·1 (16·1) | 33·3 (16·6) | 33·2 (16·4) | 35·5 (16·1) |
| Male, n (%) | 674 (57·8) | 1322 (57·3) | 1996 (57·5) | 1792 (58·9) |
| Duration of AD (years), mean (SD) | 25·0 (15·1) | 24·8 (15·6) | 24·9 (15·4) | 27·1 (15·7) |
| EASI score, mean (SD) | 32·0 (15·3) | 28·8 (16·2) | 29·9 (16·0) | 16·3 (14·8) |
| BSA score, mean (SD) | 53·2 (25·0) | 48·1 (26·1) | 49·8 (25·9) | 28·6 (25·5) |
| IGA score, n (%) | ||||
| IGA 3 | 495 (42·5) | 908 (39·4) | 1403 (40·4) | 1398 (45·9) |
| IGA 4 | 590 (50·6) | 1071 (46·4) | 1661 (47·8) | 531 (17·4) |
| Pruritus NRS, mean (SD) | 7·0 (2·2) | 6·6 (2·5) | 6·8 (2·4) | NAa |
| SCORAD, mean (SD) | 64·8 (18·9) | 60·7 (22·3) | 62·1 (21·3) | 42·0 (22·3) |
| o‐SCORAD, mean (SD) | 52·9 (15·7) | 49·5 (18·3) | 50·7 (17·5) | 35·0 (18·3) |
| POEM, mean (SD) | 19·4 (6·9) | 18·3 (7·7) | 18·7 (7·4) | 14·7 (8·0) |
| DLQI or CDLQI, mean (SD) | 13·8 (7·8) | 13·0 (8·0) | 13·3 (8·0) | 8·4 (7·1) |
AD, atopic dermatitis; BSA, body surface area; CDLQI, Children’s Dermatology Life Quality Index; DLQI, Dermatology Life Quality Index; EASI, Eczema Area and Severity Index; IGA, Investigator’s Global Assessment; NRS, numerical rating scale; OLE, open‐label extension; o‐SCORAD, objective Scoring Atopic Dermatitis; POEM, Patient‐Oriented Eczema Measure; SCORAD, Scoring Atopic Dermatitis; TCS, topical corticosteroids. aNot collected for OLE patients.